Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Konstantinos Porpodis (Thessaloniki, Greece), Kalliopi Domvri, Konstantinos Porpodis, Antonis Papaioannou, Paul Zarogoulidis, Dimitrios Dimitrios Petridis, Olga Hatzizisi, Alexandra Liaka, Violeta Kikidaki, Sofia Lampaki, Ioannis Organtzis, Konstantinos Zarogoulidis. Neutrophils and spirometry changes in COPD patients treated with roflumilast. Eur Respir J 2015; 46: Suppl. 59, 3979

Member's Comments

No comment yet.

Related content which might interest you: Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Clinical and functional effectiveness of roflumilast in severe COPD patients Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Lung function change and exacerbations in patients with COPD in the WISDOM study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 QVA149 provides superior peak lung function in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Are COPD patients with chronic dyspnea and attending pulmonary rehabilitation treated with dual bronchodilatation or not? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Effects of ciclesonide on the management of stable COPD with airway eosinophilia Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Changes of TNF-a level in bronchoalveolar fluid of patients with chronic obstructive pulmonary disease before and after the 30 days treatment with tiotropium bromide Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015 The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment Source: International Congress 2016 – Translational studies in lung disease Year: 2016 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015